Catalyst Biosciences CBIO Stock
0.51 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
19.42M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Catalyst Biosciences Price Chart
Catalyst Biosciences CBIO Financial and Trading Overview
| Catalyst Biosciences stock price | 0.51 USD |
| Previous Close | 0.23 USD |
| Open | 0.24 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 4000 |
| Day's Range | 0.24 - 0.26 USD |
| 52 Week Range | 0.19 - 2.09 USD |
| Volume | 323.9K USD |
| Avg. Volume | 206.67K USD |
| Market Cap | 9.37M USD |
| Beta (5Y Monthly) | 1.193661 |
| PE Ratio (TTM) | 1.1819048 |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | January 13, 2023 |
| 1y Target Est | N/A |
CBIO Valuation Measures
| Enterprise Value | 33.89M USD |
| Trailing P/E | 1.1819048 |
| Forward P/E | -1.6546665 |
| PEG Ratio (5 yr expected) | 0.06 |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.684 |
Trading Information
Catalyst Biosciences Stock Price History
| Beta (5Y Monthly) | 1.193661 |
| 52-Week Change | -82.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.09 USD |
| 52 Week Low | 0.19 USD |
| 50-Day Moving Average | 0.22 USD |
| 200-Day Moving Average | 0.49 USD |
CBIO Share Statistics
| Avg. Volume (3 month) | 206.67K USD |
| Avg. Daily Volume (10-Days) | 175.75K USD |
| Shares Outstanding | 37.76M |
| Float | 27.23M |
| Short Ratio | 1.71 |
| % Held by Insiders | 28.19% |
| % Held by Institutions | 13.66% |
| Shares Short | 251.78K |
| Short % of Float | 0.67% |
| Short % of Shares Outstanding | 0.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.89% |
| Return on Equity (ttm) | 38.06% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -20133000 USD |
| Net Income Avi to Common (ttm) | 6.55M USD |
| Diluted EPS (ttm) | 0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.1M USD |
| Total Cash Per Share (mrq) | 0.21 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.048 |
| Book Value Per Share (mrq) | -0.687 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27262000 USD |
| Levered Free Cash Flow (ttm) | -19967124 USD |
Profile of Catalyst Biosciences
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 611 Gateway Blvd. |
| ZIP | 94080 |
| Phone | 650 871 0761 |
| Website | https://www.catalystbiosciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Q&A For Catalyst Biosciences Stock
What is a current CBIO stock price?
Catalyst Biosciences CBIO stock price today per share is 0.51 USD.
How to purchase Catalyst Biosciences stock?
You can buy CBIO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Catalyst Biosciences?
The stock symbol or ticker of Catalyst Biosciences is CBIO.
Which industry does the Catalyst Biosciences company belong to?
The Catalyst Biosciences industry is Biotechnology.
How many shares does Catalyst Biosciences have in circulation?
The max supply of Catalyst Biosciences shares is 37.98M.
What is Catalyst Biosciences Price to Earnings Ratio (PE Ratio)?
Catalyst Biosciences PE Ratio is 0.00000000 now.
What was Catalyst Biosciences earnings per share over the trailing 12 months (TTM)?
Catalyst Biosciences EPS is 0 USD over the trailing 12 months.
Which sector does the Catalyst Biosciences company belong to?
The Catalyst Biosciences sector is Healthcare.
Catalyst Biosciences CBIO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}